2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 143

Patient Rheumatoid Arthritis Data from the Real World (PARADE) Study: Preliminary Results from an Apple Researchkit™ Mobile App-Based Real World Study in the United States
Abstract Number: 1299

Patient-Reported Disease Activity and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 337

Patient-Reported Flares Were Correctly Predicted By an Algorithm Using Machine-Learning Statistics on Activity Tracker Data on Steps, in a Longitudinal 3-Month Study of 170 Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA)
Abstract Number: 1804

Patient-Reported Outcomes and Damage Predict Mortality in Lupus
Abstract Number: 1477

Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials
Abstract Number: 2460

Patient-Reported Outcomes Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Abstract Number: 501

Patient-Reported Outcomes of Long-Term Upadacitinib Use in Patients with Rheumatoid Arthritis: Interim Analysis Results of a Phase 2, Open-Label Extension Study
Abstract Number: 336

Patient–Reported Barriers to Achieving Rheumatoid Arthritis Disease Control
Abstract Number: 2253

Patient’s Self-Monitoring of Disease Activity of Rheumatic Diseases Via Webapp – Study Design, Patient’s Perspective and Recruitment in the First 16 Months of a Swiss Multicentre, Longitudinal Study
Abstract Number: 358

Patients and Physicians Have Different Perceptions of the Relative Bother of the Symptoms and Impacts on Daily Activities in Psoriasis and Psoriatic Arthritis
Abstract Number: 152

Patients Failing to Fulfill 2016 Criteria for Fibromyalgia Represent a Truly Different Population Subset
Abstract Number: 2423

Patients with Active Rheumatoid Arthritis but Normal Levels of Acute Phase Proteins Have Altered Regulatory T Cell Function and Rapidly Progress to Biological Therapies
Abstract Number: 1522

Patients with Ankylosing Spondylitis Had Better Adalimumab Survival Than Patients with Non-Radiographic Axial Spondyloarthritis
Abstract Number: 2084

Patients with Early Onset Gout Develop Earlier Severe Joint Involvement and Metabolic Comorbid Conditions
Abstract Number: 350

Patients with Gout Consider Zero Flares over the Previous Six or Twelve Months Necessary for a Remission State

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].